RE:RE:RE:CD8+ TiLs and T-cell exhaustionMarch 16, 2024 - Further to ONCY's ASCO 2024 poster presentation ... " there has been a growing emphasis on the development of “liquid biopsy” derived biomarkers, which offer a minimally invasive means to dynamically monitor the immune status of [cancer] patients either before and/or during the course of treatment."
" ... compelling correlations between the peripheral immune status of patients both before and during ICI therapy and patient outcomes, which include response rates, progression-free survival, and overall survival [are being unveiled]. There is need for rigorous validation and standardization of these blood-based assays for broader clinical application. Integration of multiple blood-based biomarkers into comprehensive panels or algorithms also has the potential to enhance predictive accuracy."
" In some cases, studies on blood-based biomarkers have reported on how a particular peripheral measure compares with tissue approved biomarkers (e.g., PD-L1 expression and TMB) that are used for clinical decisions. More of these comparative studies are needed in this rapidly growing field. It should be noted that, while this review focused on promising advances in the field of blood-based biomarkers in NSCLC patients treated with ICI, the blood-based assays described here are not cancer specific and could be considered more widely for application in immunotherapy studies of all solid tumors. In closing, this review demonstrates the potential value that specific blood-based biomarkers have provided in predicting therapeutic responses and long-term outcomes of patients following immune checkpoint inhibitors.
https://jeccr.biomedcentral.com/articles/10.1186/s13046-024-02969-1